Citing the Mashelkar Report of 2003, it went on to say that the problems in the regulatory system in the country were primarily due to inadequate or weak drug control infrastructure at the state and central levels, inadequate testing facilities, shortage of drug inspectors, non-uniformity of enforcement, lack of specially trained cadres for specific regulatory areas, and the non-existence of a data bank.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/PIVQ08n
via IFTTT
0 comments:
Post a Comment